Business Context and Reporting Period
Revolution Medicines, Inc. (RVMD) filed a Form 8-K on December 3, 2024, reporting a significant capital raise event. The company, incorporated in Delaware and headquartered in Redwood City, California, is an emerging growth company. The filing details an underwriting agreement entered into on December 3, 2024, which closed on December 5, 2024.
Key Financial Metrics
This filing reports on a specific financing transaction rather than periodic operating results. Key metrics related to the offering include:
- Net Proceeds: Approximately $823.0 million received after deducting underwriting discounts, commissions, and estimated offering expenses.
- Shares Issued: An aggregate of 16,576,088 shares of Common Stock were sold, including the full exercise of the underwriters' option.
- Pre-Funded Warrants: 2,173,917 pre-funded warrants were issued to purchase Common Stock.
- Offering Price: $46.00 per share for Common Stock and $45.9999 per Pre-Funded Warrant.
- Underwriting Price: $43.93 per share for Common Stock and $43.9299 per Pre-Funded Warrant.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels as this is a current report on a specific event, not a quarterly or annual financial statement.
Material Changes
The primary material change is the substantial increase in the company's cash liquidity resulting from the completed public offering. The company expanded its share count by issuing over 16.5 million new shares and pre-funded warrants. Additionally, the company and its directors and executive officers entered into a 45-day lock-up agreement, restricting the sale or transfer of Common Stock without the consent of the underwriters.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking revenue projections, or management commentary on operational outlook. The primary risk disclosed relates to the indemnification of underwriters against liabilities under the Securities Act of 1933. The transaction was executed under an automatically effective shelf registration statement (Form S-3).
Investor Verification Checklist
- Verify the final net proceeds of $823.0 million against the company's updated cash balance in subsequent filings.
- Confirm the total diluted share count following the issuance of 16,576,088 shares and 2,173,917 pre-funded warrants.
- Monitor the expiration of the 45-day lock-up period for directors and executive officers to assess potential selling pressure.
- Review the use of proceeds disclosed in the related prospectus supplement to ensure alignment with the company's stated strategic priorities.